Serum neprilysin and recurrent admissions in patients with heart failure

Journal of the American Heart Association

Volumn 6, Issue 8, 2017, Pages

  Núñez, Julio ^a,b,c   Núñez, Eduardo ^a,b   Barallat, Jaume ^d   Bodí, Vicent ^a,b   Miñana, Gema ^a,b,c   Cruz Pastor, M ^d   Sanchis, Juan ^a,b,c   Lupón, Josep ^c,d,e   Bayes Genis, Antoni ^c,d,e  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CIBER Cardiovascular ^*  (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Heart failure; Neprilysin; Readmission

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; MEMBRANE METALLOENDOPEPTIDASE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH SERVICE; RECURRENT DISEASE; RISK FACTOR; AGED; BLOOD; CAUSE OF DEATH; EPIDEMIOLOGY; HOSPITAL READMISSION; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; SPAIN; TIME FACTOR; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CAUSE OF DEATH; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PATIENT READMISSION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SPAIN; TIME FACTORS; UP-REGULATION;

EID: 85030722254     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.005712     Document Type: Article

References (22)

1. United States Department of Health and Human Services. Hospital quality overview. Available at: http://www.hospitalcompare.hhs.gov/staticpages/for consumers/for-consumers.aspx. Accessed March 7, 2012
2. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126:501-506
3. Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, Krumholz HM. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med. 2008;168:1371-1386
4. Frizzell JD, Liang L, Schulte PJ, Yancy CW, Heidenreich PA, Hernandez AF, Bhatt DL, Fonarow GC, Laskey WK. Prediction of 30-day all-cause readmissions in patients hospitalized for heart failure: comparison of machine learning and other statistical approaches. JAMA Cardiol. 2017;2:204-209
5. Anker SD, McMurray JJ. Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? Eur Heart J. 2012;33:2764-2765
6. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Östergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16:33-40
7. Bayes-Genis A, Núñez J, Núñez E, Martínez JB, Ferrer MP, de Antonio M, Zamora E, Sanchis J, Rosés JL. Multi-biomarker profiling and recurrent hospitalizations in heart failure. Front Cardiovasc Med. 2016;3:37
8. Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68:639-653
9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004
10. Bayes-Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657-665
11. Bayés-Genís A, Barallat J, Pascual D, Nuñez J, Miñana G, Sánchez-Mas J, Galan A, Sanchis J, Zamora E, Pérez-Martínez MT, Lupón J. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. JACC Heart Fail. 2015;3:641-644
12. Bayes-Genis A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Gastelurrutia P, Vila J, Peñafiel J, Gálvez-Montón C, Lupón J. Multimarker strategy for heart failure prognostication. Value of neurohormonal biomarkers: neprilysin vs NT-proBNP. Rev Esp Cardiol (Engl Ed). 2015;68:1075-1084
13. Xu X, Hardin JW. Regression models for bivariate count outcomes. Stata J. 2016;16:301-315
14. Royston P, Sauerbrei W. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley; 2008
15. Di Tano G, De Maria R, Gonzini L, Aspromonte N, Di Lenarda A, Feola M, Marini M, Milli M, Misuraca G, Mortara A, Oliva F, Pulignano G, Russo G, Senni M, Tavazzi L; IN-HF Outcome Investigators. The 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry. Eur J Heart Fail. 2015;17:1032-1041
16. Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014;2:289-297
17. Núñez J, Núñez E, Sanchis J. Spironolactone in patients with heart failure and preserved ejection fraction. Rev Clin Esp. 2016;216:111
18. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bélohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzălez-Medina A, Hağege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61
19. Núñez J, Llăcer P, Bertomeu-González V, Bosch MJ, Merlos P, García-Blas S, Montagud V, Bodí V, Bertomeu-Martínez V, Pedrosa V, Mendizábal A, Cordero A, Gallego J, Palau P, Miñana G, Santas E, Morell S, Llăcer A, Chorro FJ, Sanchis J, Fácila L; CHANCE-HF Investigators. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail. 2016;4:833-843
20. Johnson AR, Coalson JJ, Ashton J, Larumbide M, Erdös EG. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. Am Rev Respir Dis. 1985;132:1262-1267
21. Núñez J, Núñez E, Miñana G, Carratalá A, Sanchis J, Lupón J, Barallat J, Pastor MC, Pascual-Figal D, Bayés-Genís A. Serum neprilysin and recurrent hospitalizations after acute heart failure. Int J Cardiol. 2016;220:742-744
22. Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail. 2016;18:89-93